The lack of PKM2 expression in benign tissue and the inability of the PKM2 activators to induce PK activity in the presence of other PK isotypes [20] make these drugs tempting to investigate aiming to open a new therapeutic window through targeting cancer metabolism [29]. Here, PKM is linked to cancer.